MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Collaboration revenue -related party$47,033K (74.04%↑ Y/Y)Collaboration revenue$12,586K (3292.45%↑ Y/Y)Grant revenue$7,183K (-65.10%↓ Y/Y)Total revenues$66,802K (39.24%↑ Y/Y)Interest income$2,512K (-46.95%↓ Y/Y)Other income(expense), net$7K (-88.33%↓ Y/Y)Income (loss) fromoperations$6,314K (108.61%↑ Y/Y)Total other income,net$2,519K (-47.47%↓ Y/Y)Total operatingexpenses$60,488K (-50.15%↓ Y/Y)Net income (loss)before income taxes$8,833K (112.88%↑ Y/Y)Research and development$38,467K (-60.24%↓ Y/Y)General andadministrative$21,176K (-10.66%↓ Y/Y)Impairment of long-termasset$587K Restructuring$258K (-70.58%↓ Y/Y)Net income (loss)and comprehensive...$8,572K (112.50%↑ Y/Y)Income tax expense$261K Severance and otheremployee costs$258K
Income Statement
source: myfinsight.com

Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics, Inc. (SPRO)